Quick Summary
- Immutep shares skyrocketed more than 101% following FDA Orphan Drug Designation approval for eftilagimod alfa (efti) in treating soft tissue sarcoma.
- The orphan designation applies to soft tissue sarcoma, a rare malignancy impacting under 200,000 Americans annually.
- Key advantages include seven-year market exclusivity post-approval, tax incentives, waived regulatory fees, and enhanced FDA guidance.
- Supporting evidence came from the EFTISARC-NEO Phase II clinical trial, which successfully achieved its primary objective in 38 participants.
- The designation arrives after Immutep discontinued its TACTI-004 Phase III study, a move projected to preserve capital reserves past mid-2027.
Shares of Australian biotechnology firm Immutep exploded higher on Wednesday following confirmation that the U.S. Food and Drug Administration granted Orphan Drug Designation to eftilagimod alfa, the company’s primary oncology candidate.
The company, trading on the Australian Securities Exchange, experienced a remarkable 101.3% surge to A$0.079 during midweek trading activity.
The regulatory designation specifically applies to efti’s application in soft tissue sarcoma (STS), a rare malignancy representing a significant area of unmet therapeutic need across the United States.
Receiving Orphan Drug Designation brings substantial commercial and regulatory benefits: specialized FDA consultation, possible tax incentives, exemptions from various user fees, and a critical seven-year period of marketing exclusivity upon final approval.
The agency’s determination drew upon clinical evidence generated through the EFTISARC-NEO Phase II study. This investigation evaluated efti combined with radiation therapy and Merck’s KEYTRUDA (pembrolizumab) in soft tissue sarcoma patients with resectable tumours prior to surgical intervention.
Among 38 assessable participants, the study successfully reached its primary efficacy measure. Researchers documented a median tumour hyalinization/fibrosis rate of 51.5%, substantially exceeding the predetermined 35% threshold and dramatically outperforming the historical 15% rate typically observed with radiation therapy as a standalone treatment.
These encouraging outcomes were consistent across various sarcoma subtypes. The treatment demonstrated a manageable safety profile, with no documented delays to scheduled surgical procedures.
TACTI-004 Discontinuation
This encouraging regulatory milestone follows Immutep’s recent decision to terminate its TACTI-004 Phase III clinical program in early March. That study was investigating efti’s efficacy in first-line non-small cell lung cancer patients.
An Independent Data Monitoring Committee advised discontinuation after determining the trial was unlikely to meet its efficacy endpoints. The organization is now executing an organized shutdown of TACTI-004 operations.
Immutep indicated that terminating the trial should significantly extend its financial runway well past the previously communicated Q2 2027 timeline.
Development Portfolio and Financial Position
Beyond its soft tissue sarcoma and lung cancer initiatives, Immutep is advancing five distinct LAG-3 therapeutic programs. Among these, IMP761 is currently undergoing Phase I evaluation for autoimmune disease applications.
The organization reported a net operating loss of A$61.4 million during the 2025 fiscal period, representing an increase from the A$42.7 million deficit recorded in 2024.
As a pre-revenue biotechnology enterprise, Immutep continues requiring external capital infusions to support ongoing research initiatives and clinical development activities.
The company maintains strategic collaborations with leading pharmaceutical corporations, including Merck (MSD), to facilitate pipeline advancement.
The EFTISARC-NEO clinical trial results that underpinned Wednesday’s FDA designation also incorporated translational research findings aligned with efti’s proposed mechanism of action — immune system activation through LAG-3 engagement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
